| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐114 mm Hg after run‐in; 6‐week double‐blind treatment |
| Participants |
Trandolapril 4 mg: n=159(106 males,53 females); mean age=54.3 years; baseline SBP=151.8(14.8) mm Hg, DBP=101.3(5.0) mm Hg;
Placebo: n=152(103 males,49 females); mean age=53.8 years; baseline SBP=153.6(13.4) mm Hg, DBP=100.5(4.5) mm Hg |
| Interventions |
Trandolapril 4 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change reported, endpoint BP and SD not reported; SD of change values reported are low; imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Table 2, p. 325; Jadad score=3; funding source= Knoll Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
